Status:
UNKNOWN
Deprescribing of Symptomatic Medications in Rehabilitative or Subacute Care Patients
Lead Sponsor:
Bright Vision Hospital
Conditions:
Polypharmacy
Adverse Drug Reaction
Eligibility:
All Genders
Phase:
NA
Brief Summary
Deprescribing is a systematic method of withdrawing potentially inappropriate or unnecessary medications and is warranted in the elderly due to the high prevalence of polypharmacy. In particular, symp...
Detailed Description
Deprescribing is a systematic process of identifying and withdrawing drugs, which are potentially or currently causing more harm than benefit to patients, based on each individual patient's condition,...
Eligibility Criteria
Inclusion
- All patients, regardless of age, who were on at least one of the following target symptomatic control medications for deprescribing: acid suppressants/proton pump inhibitors (PPIs), laxatives, analgesics (paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), codeine, tramadol) and antiemetics
Exclusion
- Patients with terminal illness or cancer and patients with documented clinically significant dementia and had no accompanying caregiver
Key Trial Info
Start Date :
April 5 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03354845
Start Date
April 5 2016
End Date
January 31 2018
Last Update
November 28 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.